XRAY Stock Analysis: Dentsply Sirona | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 1.706m USD | 12M Return: -26.7% | US24906P1093 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 47.9M
EPS Trend: -92.9%
Qual. Beats: 1
Rev. Trend: -93.2%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Dentsply Sirona (NASDAQ: XRAY) is a global dental and healthcare products company that develops, manufactures, and markets dental equipment, dental products, and healthcare consumables used in urology and enterology. The company operates through four reportable segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. Its product portfolio spans imaging systems, treatment centers, intraoral scanners, 3D printers, endodontic instruments, clear aligner solutions, dental implants, and catheters for urinary retention and irrigation.
The company sells primarily to dental professionals, clinics, and hospitals, with a business model increasingly oriented toward digital and cloud-enabled dentistry through offerings such as the CEREC chairside restoration system, SureSmile clear aligners, and the DS Core visualization platform. As a small-cap stock in the Health Care Supplies sub-industry, XRAY competes within a specialized niche of the broader medical device market, combining traditional consumables with higher-margin connected dental technology.
Dentsply Sirona was founded in 1877 and is headquartered in Charlotte, North Carolina. The company was formerly known as Dentsply International Inc. and adopted its current name in February 2016 following the merger with Sirona Dental Systems.
- SureSmile clear aligner growth challenges Invisalign market dominance
- Dental equipment demand softens as practices cut capital spending
- Activist investor pressure drives cost cuts and margin improvement
| Net Income: -546.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.47 > 1.0 |
| NWC/Revenue: 20.40% < 20% (prev 21.79%; Δ -1.40% < -1%) |
| CFO/TA 0.06 > 3% & CFO 319.0m > Net Income -546.0m |
| Net Debt (2.16b) to EBITDA (172.0m): 12.56 < 3 |
| Current Ratio: 1.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (200.5m) vs 12m ago 0.60% < -2% |
| Gross Margin: 49.52% > 18% (prev 51.68%; Δ -2.16% > 0.5%) |
| Asset Turnover: 64.63% > 50% (prev 60.49%; Δ 4.14% > 0%) |
| Interest Coverage Ratio: -2.81 > 6 (EBIT TTM -256.0m / Interest Expense TTM 91.0m) |
| A: 0.14 (Total Current Assets 1.93b - Total Current Liabilities 1.19b) / Total Assets 5.20b |
| B: -0.30 (Retained Earnings -1.54b / Total Assets 5.20b) |
| C: -0.05 (EBIT TTM -256.0m / Avg Total Assets 5.64b) |
| D: 0.35 (Book Value of Equity 1.35b / Total Liabilities 3.85b) |
| Altman-Z'' = 0.04 = B |
| DSRI: 0.97 (Receivables 620.0m/646.0m, Revenue 3.64b/3.67b) |
| GMI: 1.04 (GM 51.68% / 49.52%) |
| AQI: 0.86 (AQ_t 0.44 / AQ_t-1 0.51) |
| SGI: 0.99 (Revenue 3.64b / 3.67b) |
| TATA: -0.17 (NI -546.0m - CFO 319.0m) / TA 5.20b) |
| Beneish M = -3.12 (Cap -4..+1) = AA |
As of October 10, 2026, the stock is trading at USD 8.83 with a total of 4,219,770 shares traded. Over the past week, the price has changed by +1.85%, over one month by -17.63%, over three months by -25.74% and over the past year by -26.70%.
Current recommended Stop Loss: 8.30 (which is 6% or 1.5 ATR below the current price).
Dentsply Sirona has received a consensus analysts rating of 3.29. Therefore, it is recommended to hold XRAY.
- StrongBuy: 2
- Buy: 2
- Hold: 12
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 13.7 | 55.5% |
P/E Forward = 6.3291
P/S = 0.4684
P/B = 1.4431
P/EG = 0.633
Revenue TTM = 3.64b USD
EBIT TTM = -256.0m USD
EBITDA TTM = 172.0m USD
Long Term Debt = 2.00b USD (from longTermDebt, last quarter)
Short Term Debt = 228.0m USD (from shortTermDebt, last quarter)
Debt = 2.40b USD (from shortLongTermDebtTotal, last quarter) + Leases 88.0m
Net Debt = 2.16b USD (calculated: Debt 2.40b - CCE 239.0m)
Enterprise Value = 3.87b USD (1.71b + Debt 2.40b - CCE 239.0m)
Interest Coverage Ratio = -2.81 (Ebit TTM -256.0m / Interest Expense TTM 91.0m)
EV/FCF = 27.05x (Enterprise Value 3.87b / FCF TTM 143.0m)
FCF Yield = 3.70% (FCF TTM 143.0m / Enterprise Value 3.87b)
FCF Margin = 3.93% (FCF TTM 143.0m / Revenue TTM 3.64b)
Net Margin = -14.99% (Net Income TTM -546.0m / Revenue TTM 3.64b)
Gross Margin = 49.52% ((Revenue TTM 3.64b - Cost of Revenue TTM 1.84b) / Revenue TTM)
Gross Margin QoQ = 54.90% (prev 48.52%)
Tobins Q-Ratio = 0.74 (Enterprise Value 3.87b / Total Assets 5.20b)
Interest Expense / Debt = 3.79% (Interest Expense 91.0m / Debt 2.40b)
Taxrate = 50.0% (36.0m / 72.0m)
NOPAT = -128.0m (EBIT -256.0m * (1 - 50.00%)) [loss with tax shield]
Current Ratio = 1.63 (Total Current Assets 1.93b / Total Current Liabilities 1.19b)
Debt / Equity = 1.78 (Debt 2.40b / totalStockholderEquity, last quarter 1.35b)
Debt / EBITDA = 12.56 (Net Debt 2.16b / EBITDA 172.0m)
Debt / FCF = 15.11 (Net Debt 2.16b / FCF TTM 143.0m)
Total Stockholder Equity = 1.37b (last 4 quarters mean from totalStockholderEquity)
RoA = -9.69% (Net Income -546.0m / Total Assets 5.20b)
RoE = -39.81% (Net Income TTM -546.0m / Total Stockholder Equity 1.37b)
RoCE = -7.60% (EBIT -256.0m / Capital Employed (Equity 1.37b + L.T.Debt 2.00b))
RoIC = -3.15% (negative operating profit) (NOPAT -128.0m / Invested Capital 4.06b)
WACC = 5.06% (E(1.71b)/V(4.11b) * Re(9.50%) + D(2.40b)/V(4.11b) * Rd(3.79%) * (1-Tc(0.50)))
Discount Rate = 9.50% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.80 | Cagr: -1.72%
[DCF] Terminal Value 75.91% ; FCFF base≈141.0m ; Y1≈145.8m ; Y5≈163.9m
[DCF] Fair Price = 1.87 (EV 2.53b - Net Debt 2.16b = Equity 373.0m / Shares 199.4m; r=8.35% [WACC [floored]]; 5y FCF grow 3.62% → 2.50% )
EPS Correlation: -92.85 | EPS CAGR: -9.51% | SUE: 1.83 | # QB: 1
Revenue Correlation: -93.20 | Revenue CAGR: -3.52% | SUE: 0.39 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.31 | Chg30d=-0.48% | Revisions=-25% | Analysts=15
EPS current Year (2026-12-31): EPS=1.50 | Chg30d=-0.27% | Revisions=-25% | GrowthEPS=-6.3% | GrowthRev=-2.9%
EPS next Year (2027-12-31): EPS=1.51 | Chg30d=-0.65% | Revisions=-50% | GrowthEPS=+0.6% | GrowthRev=+1.5%
[Analyst] Revisions Ratio: -62% (up=0, down=5)